-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
5 views
AbbVie's top line is stable post-Humira, with Skyrizi and Rinvoq driving growth, but margin recovery remains uncertain and slow. Pipeline and acquisitions support long-term growth, but macro risks like IRA pricing and pharma tariffs could pressure margins further. Dividend yield is attractive, but potential recent cash flow weakness raises questions about sustainability if not transitory; capital allocation needs watching.
